AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 231 min read$RDY

Dr. Reddy’s outlines semaglutide relaunch in November 2026 and reiterates 6M-7M devices target (NYSE:RDY)

Dr. Reddy's Laboratories (RDY) reported a 1.5% year-over-year revenue decline, with Q2 FY '27 revenue at INR 8,671 crores (USD 905M) and an EBITDA margin of 20.6%. The company plans to relaunch semaglutide in November 2026 and reiterated its target of 6M-7M devices.

Original reporting
seekingalpha.com
Published Oct 23, 2026, 11:10 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 11:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RDY
Bearish
high confidence
Mentioned
$RDY
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$RDYBearishMed
01

Why it matters

The disclosed revenue decline and margin level are new data points for investors.

02

Market read

Fresh earnings numbers with a revenue miss could move the stock and affect the sector.

03

What to watch

Currency fluctuations and one‑off expenses were not detailed.

Relevance 7/10Novelty 7/10Timing: after-hours release

Background

The article is an AI‑generated earnings call summary from Seeking Alpha.

Company-level read

Ticker impact

$RDYBearishHigh confidence
Context

Dr. Reddy's reported a 1.5% YoY revenue decline and 20.6% EBITDA margin for Q2 FY27, indicating weaker performance.

Expected impact

likely downside as market prices in the revenue decline

Evidence & confidence

Earnings numbers are fresh and show a decline, which typically triggers sell pressure.

Market effects

Sector

Indian pharma sector may see broader scrutiny after the miss.

Regional

Potential modest impact on Indian market indices.

Global

Limited global effect, mainly relevant to investors in emerging markets.

Counterpoint

What could challenge this read

If the decline is temporary, the stock could rebound on cost control.

Key entities

  • company
    Dr. Reddy's Laboratories Limited

    Indian pharmaceutical company reporting FY27 Q2 results.

Read at source← All news

StoryDr. Reddy's plans November 2026 semaglutide relaunch and reiterates 6‑7 million device target

Also covered by

1 outlet

Related articles

OCT 23
$RDYHigh

DR REDDYS LABORATORIES LTD (RDY): Financial results for H1 2027

DR REDDYS LABORATORIES LTD (RDY) furnished an SEC Form 6-K — earnings release. Exhibit 99.2 CONTACT DR. REDDY’S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AISHWARYA SITHARAM SANTOSH VYAS aishwaryasitharam@drreddys.com santoshvyas@drreddys.com Dr. Reddy’s Q2 & H1FY27 Financia

SEC EDGAR 6-K2 min
OCT 23
$RDYMed

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

Dr. Reddy's Laboratories (NYSE: RDY) expects to relaunch semaglutide in November 2026, with most supply going to Canada. Q2 North America generics revenue was $264M, down 29% YoY. The company received FDA approval for its rituximab biosimilar and launched nivolumab in India. Net cash as of Sept. 30 was INR 2,502 crore, with full-year capex expected at INR 1,600-1,700 crore.

finance.yahoo.com3 min
OCT 23
$RDYHigh

Dr. Reddy's Laboratories (RDY) Stock Falls on Q2 2027 Earnings

Dr. Reddy's Laboratories (RDY) reported Q2 2027 earnings with revenue down 8.8% to $903.9M, operating profit down 71.6% to $132.2M, and net income down 40.4% to $96.4M. Cash from operations fell 67.4% to $55.2M. The stock dropped 2.69% in morning trading. Institutional investors showed mixed activity, with some adding and others reducing their positions.

quiverquant.com1 min
OCT 23
$RDYMed

Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript

Dr. Reddy's reported Q2 2027 earnings with a 52.1% gross margin increase sequentially but a 254 basis point year-over-year decline due to lower Lenalidomide sales. EBITDA margin was 20.6%, and profit after tax was ₹9.25 crores. The company highlighted double-digit growth in North America and emerging markets, new product launches, and strategic partnerships. Operating working capital increased to $1.53 billion, with a net cash surplus of ₹2.5 thousand crores.

finance.yahoo.com3 min
OCT 23
$RDYMed

Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.

investing.com2 min
OCT 23
$RDYMed

Dr. Reddy's Laboratories Profit Drops In Q2

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

rttnews.com1 min